AOD9604 | 30 mg pen

OD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone (hGH 176–191), studied for its role in lipid metabolism and adipose-tissue regulation. In research settings, it has been evaluated in models where lipolysis, fat-mass reduction, and metabolic efficiency are measured as endpoints. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.

Supports

Lipid metabolism assessed via lipolysis and fatty-acid mobilization markers.
Adipose-tissue reduction endpoints tracked in body-composition research models.
Fat oxidation pathways studied through energy-utilization and metabolic flux frameworks.
Non-IGF-1 fat-regulation mechanisms evaluated independently of growth signaling pathways.
Body-weight and fat-mass changes measured in controlled metabolic studies.

DESCRIPTION

AOD-9604 is a synthetic peptide corresponding to amino acids 176–191 of human growth hormone. It has been modified to isolate fat-metabolism signaling pathways while minimizing broader endocrine activity typically associated with full-length hGH. In experimental research, AOD-9604 has been studied for its ability to stimulate lipolysis and inhibit lipogenesis in adipose tissue. Unlike full growth hormone, it does not significantly elevate IGF-1 levels in most study models, making it relevant in metabolic research where growth-independent fat modulation is evaluated. AOD-9604 is presented here for controlled research and educational context only and is not marketed as a therapeutic intervention.

CLINICAL STATUS

AOD-9604 has been evaluated in both preclinical and human clinical research settings, including studies focused on obesity and metabolic regulation. Outcomes in human trials have been variable and dependent on study design and dosing protocols. It is not widely approved as a general therapeutic product.
Evidence type: Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ✘

MECHANISM OF ACTION

Mechanistic models of AOD-9604 focus on its interaction with pathways involved in lipid metabolism. The peptide has been shown in research settings to stimulate lipolysis and inhibit the formation of new fat cells, particularly within adipose tissue. Unlike full-length growth hormone, AOD-9604 does not significantly activate IGF-1–mediated growth pathways, allowing selective targeting of fat metabolism. Effects are typically measured through changes in fat mass, lipid markers, and metabolic efficiency.

BENEFITS

Targeted Fat Metabolism Support: AOD-9604 has been studied for its ability to directly influence fat metabolism at the adipose-tissue level.
Lipolysis Stimulation: Experimental models show increased fat breakdown through activation of lipid-mobilization pathways.
Non-IGF-1 Pathway Activity: Does not significantly elevate IGF-1 in most research settings, supporting growth-independent fat modulation.
Adipose Tissue Reduction: Preclinical and clinical research has explored reductions in fat mass under controlled conditions.
Metabolic Efficiency Research: Studies have evaluated improvements in fat utilization and energy metabolism.
Body Composition Applications: Commonly used in research focused on fat loss, metabolic health, and body-composition outcomes.

RESEARCH DATA

Study/model | Reported effect
Human obesity trials | Mixed results on fat reduction depending on protocol
Rodent metabolic models | Increased lipolysis and reduced fat accumulation
In vitro adipocyte studies | Inhibition of lipogenesis and stimulation of fat breakdown
Metabolic pathway analysis | Changes in lipid utilization and energy markers observed

STACK SUGGESTIONS

GLP-1 analogues (appetite and metabolic pathway comparison frameworks)
L-Carnitine (fatty-acid transport and oxidation studies)
NAD+ (energy metabolism and mitochondrial function endpoints)
Stacks discussed are for experimental design only, not safety or efficacy guidance.

POSSIBLE SIDE EFFECTS

Injection-site reactions including redness or discomfort
Mild metabolic adjustments depending on study protocols
Occasional fatigue or transient systemic effects
Responses vary depending on experimental conditions

SCIENTIFIC REFERENCES

AOD-9604 obesity clinical trials — Human studies
Growth hormone fragment (176–191) metabolic research — Mechanistic studies
Adipocyte lipolysis and lipogenesis regulation — In vitro data
Metabolic pathway studies involving AOD-9604 — Preclinical research

CAUTIONS

For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease. Not approved for general medical use. Outcomes vary based on experimental design and metabolic conditions. Consult a qualified professional for any health-related decisions.